Evoke Pharma (NASDAQ:EVOK) Upgraded at Wall Street Zen

Evoke Pharma (NASDAQ:EVOK) was upgraded by stock analysts at Wall Street Zen to a “hold” rating in a note issued to investors on Saturday.

EVOK has been the subject of several other research reports. Laidlaw downgraded shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (e+)” rating on shares of Evoke Pharma in a report on Monday. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Evoke Pharma Stock Up 0.4%

Shares of EVOK opened at $11.00 on Friday. The company has a market capitalization of $18.92 million, a price-to-earnings ratio of -5.31 and a beta of -0.15. Evoke Pharma has a 52-week low of $1.94 and a 52-week high of $11.00. The stock has a 50 day moving average price of $8.89 and a 200 day moving average price of $6.01.

Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Thursday, November 13th. The specialty pharmaceutical company reported ($0.45) earnings per share for the quarter, hitting the consensus estimate of ($0.45). Evoke Pharma had a negative net margin of 36.23% and a negative return on equity of 101.40%. The business had revenue of $4.28 million during the quarter, compared to the consensus estimate of $4.33 million.

Insider Buying and Selling

In other Evoke Pharma news, major shareholder Roger M. Klein sold 9,000 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $10.65, for a total transaction of $95,850.00. Following the completion of the sale, the insider directly owned 29,000 shares of the company’s stock, valued at approximately $308,850. This trade represents a 23.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.29% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently bought a new position in Evoke Pharma stock. National Wealth Management Group LLC acquired a new stake in Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to its most recent filing with the SEC. The firm acquired 80,130 shares of the specialty pharmaceutical company’s stock, valued at approximately $398,000. National Wealth Management Group LLC owned about 5.14% of Evoke Pharma at the end of the most recent reporting period.

About Evoke Pharma

Evoke Pharma, Inc is a clinical-stage specialty pharmaceutical company focused on developing novel therapies for gastrointestinal (GI) motility disorders. The company’s lead product candidate, relamorelin, is a selective ghrelin receptor agonist designed to restore gastric motility and accelerate gastric emptying in conditions such as diabetic gastroparesis. Relamorelin has been granted orphan drug designation by the U.S. Food and Drug Administration and has demonstrated proof-of-concept activity in multiple clinical trials, positioning it as a promising treatment for patients with impaired GI function.

In addition to relamorelin, Evoke Pharma is advancing earlier-stage programs targeting metabolic and GI conditions, leveraging its expertise in peptide chemistry and receptor pharmacology.